Results 41 to 50 of about 4,339 (169)

Myelodysplastic pure red cell aplasia [PDF]

Blood, 2021
Zhaodong, Xu, Rosemary, Mueller
openaire   +2 more sources

Good 's Syndrome with Pneumocystis Jiroveci Lymphadenitis and Pure Red Cell Aplasia

Journal of Microbiology and Infectious Diseases, 2016
Pneumocystis jiroveci lymphadenitis is a rare manifestation of extrapulmonary pneumocystosis. A case of recurrent infection with lymphadenitis caused by Pneumocystis jiroveci in a middle-aged patient is described.
Jintana - Srisompong, Torpong - Thongngarm, Popchai - Ngamskulrungroj, Ruchira - Ruangchira-urai, Adhiratha - Boonyasiri   +4 more
doaj   +1 more source

A pregnant woman with thymoma-associated pure red cell aplasia

BMC Pregnancy and Childbirth, 2022
Background Pure red cell aplasia (PRCA) is a hematological disorder characterized by anemia with severe reticulocytopenia caused by a marked reduction in erythroid precursors in the bone marrow.
Megumi Shibata, Kayoko Kaneko, Nagayoshi Umehara, Hitoshi Matsui, Toshinao Kawai, Hisaya Nakadate, Atsuko Murashimia, Haruhiko Sago   +7 more
doaj   +1 more source

Acquired pure red cell aplasia: unraveling the immune pathogenesis

Journal of Bio-X Research, 2023
Acquired pure red cell aplasia (aPRCA) is a rare hematological disorder characterized by normochromic, normocytic anemia, reticulocytopenia, and the absence of erythroblasts. The pathogenesis of aPRCA has remained elusive.
Mengyuan Liu, Tian Zhang, Xifeng Dong, Huaquan Wang   +3 more
doaj   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, Volume 101, Issue 7, Page 1597-1604, July 2026.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source

Pure Red Cell Aplasia Following Interleukin-2 Therapy

Journal of Investigative Medicine High Impact Case Reports, 2016
A 61-year-old woman with metastatic renal cell carcinoma underwent systemic treatment with high-dose interleukin-2 (IL-2). Anemia requiring transfusion of 1 unit of packed red blood cells (PRBCs) was required during the second week of IL-2 therapy.
Janice P. Dutcher MD, Wen Fan MD, PhD, Peter H. Wiernik MD   +2 more
doaj   +1 more source

A case report of soluble A antigen confounding the blood type in a haplo‐identical hematopoietic stem cell transplant patient with graft‐versus‐host disease

Transfusion, Volume 66, Issue 7, Page 1438-1443, July 2026.
Abstract Background ABO‐incompatible (ABOi) hematopoietic stem cell transplantation (HSCT) is often associated with ABO discrepancies post‐HSCT. Re‐emergence of the patient's original type post‐HSCT may signal graft loss, disease relapse, recent transfusion, or soluble ABO antigen.
Sheri Hugan, Nada Naiyer, Laura Cooling
wiley   +1 more source

Rational management approach to pure red cell aplasia

Haematologica, 2018
Pure red cell aplasia is an orphan disease, and as such lacks rationally established standard therapies. Most cases are idiopathic; a subset is antibody-mediated.
Suresh Kumar Balasubramanian, Meena Sadaps, Swapna Thota, Mai Aly, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Valeria Visconte, Tomas Radivoyevitch, Jaroslaw P. Maciejewski   +8 more
doaj   +1 more source

International multicentre evaluation of a new anti‐idiotypic anti‐daratumumab for resolving pre‐transfusion interferences

Vox Sanguinis, Volume 121, Issue 7, Page 1065-1075, July 2026.
Abstract Background and Objectives Daratumumab, a therapeutic human anti‐CD38 monoclonal antibody, improves multiple myeloma outcomes but interferes with pre‐transfusion testing by binding CD38 on reagent red blood cells (RBCs), potentially masking clinically significant alloantibodies.
Arnaud Reggiani, Sofia Lejon Crottet, Sophie Waldvogel, Charlotte Engström, Serelina Coluzzi, Antonella Matteocci, Janis R. Hamilton, Levent Tufan Kumas, Karen M. K. de Vooght, Jill R. Storry, Jennylyn Flores, Núria Nogués, Carlos Cotorruelo, Molly Rutherford, Eveline B. Nilsen, Monika Pelc‐Kłopotowska, Jolanta Korzeniowska, Alessandra Baffa, Inna Sareneva, Nor Hafizah Ahmad, Katarzyna Szczudlo, Athif Rahman, Laser Sanal, Lise Jørgensen, Karolina Majewska Rochowiak, Monika Salwierz, Elisaveta Grancharova, Bojana Zivkovic, Jessica Alvarez, Mareike Riedl, Achim Knappik   +30 more
wiley   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, Volume 13, Issue 35, 24 June 2026.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source